Medexus Pharmaceuticals Inc
OTC:MEDXF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Medexus Pharmaceuticals Inc
OTC:MEDXF
|
CA |
|
V
|
Vivendi SE
DUS:VVU
|
FR |
|
Zebra Technologies Corp
F:ZT1A
|
US |
|
O
|
Otis Worldwide Corp
F:4PG
|
US |
|
H
|
Hewlett Packard Enterprise Co
F:2HP
|
US |
|
M
|
Mitsui Fudosan Co Ltd
XMUN:MFU
|
JP |
|
S
|
Sunshine Insurance Group Co Ltd
HKEX:6963
|
CN |
|
A
|
Ascot Resources Ltd
XBER:BHQ
|
CA |
|
B
|
Banco Bilbao Vizcaya Argentaria SA
MIL:BBVA
|
ES |
|
Viva Energy Group Ltd
ASX:VEA
|
AU |
Wall St Price Targets
MEDXF Price Targets Summary
Medexus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for MEDXF is 4.74 USD with a low forecast of 3.84 USD and a high forecast of 5.32 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is MEDXF's stock price target?
Price Target
4.74
USD
According to Wall Street analysts, the average 1-year price target for MEDXF is 4.74 USD with a low forecast of 3.84 USD and a high forecast of 5.32 USD.
What is the Revenue forecast for Medexus Pharmaceuticals Inc?
Projected CAGR
11%
Over the last 12 years, the compound annual growth rate for Revenue has been 37%. The projected CAGR for the next 8 years is 11%.
What is the Operating Income forecast for Medexus Pharmaceuticals Inc?
Projected CAGR
33%
The compound annual growth rate for Operating Income over the next 5 years is 33%.
What is the Net Income forecast for Medexus Pharmaceuticals Inc?
Projected CAGR
119%
The compound annual growth rate for Net Income over the next 3 years is 119%.
